Goltz, D., Gevensleben, H., Dietrich, J., Ellinger, J., Landsberg, J., Kristiansen, G., & Dietrich, D. (2016). Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncoimmunology.

Goltz, Diane, Heidrun Gevensleben, Jörn Dietrich, Jörg Ellinger, Jennifer Landsberg, Glen Kristiansen, e Dimo Dietrich. "Promoter Methylation of the Immune Checkpoint Receptor PD-1 (PDCD1) Is an Independent Prognostic Biomarker for Biochemical Recurrence-free Survival in Prostate Cancer Patients Following Radical Prostatectomy." Oncoimmunology 2016.

Goltz, Diane, et al. "Promoter Methylation of the Immune Checkpoint Receptor PD-1 (PDCD1) Is an Independent Prognostic Biomarker for Biochemical Recurrence-free Survival in Prostate Cancer Patients Following Radical Prostatectomy." Oncoimmunology 2016.